Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma.
The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.
On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).
Four years ago, Deborah Bartlett of New Haven, Connecticut (overall #11 on Asthma Capitals), was diagnosed with severe persistent asthma. Combined with her pollen and mold allergies, as well as COPD, breathing can be a real challenge.
The Asthma and Allergy Foundation of America (AAFA) conducted the My Life With Asthma survey to highlight the challenges people with asthma, especially severe asthma, face. We found that people with asthma have concerns beyond their physical health. Many deal with fear and worry.
Last year’s top Asthma Capital, Springfield, Massachusetts, is again the most challenging place in the U.S. to live with asthma. To get a better understanding of the asthma problem there, we talked with a local family, senator, allergist and city councilor.
Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.
In this essay, you’ll hear from Peter DeMarco of Boston, Massachusetts, who lost his wife, Laura Levis, to asthma. Boston ranks #8 on our 2019 Asthma Capitals report. It has such a high ranking because of a high number of people with asthma and asthma-related deaths.
On May 7, 2019, World Asthma Day, the Asthma and Allergy Foundation of America (AAFA) released its 2019 Asthma Capitals Report™. This report ranks the top 100 most challenging places in America to live with asthma.
Each May since 1984, the Asthma and Allergy Foundation of America (AAFA) has declared May to be National Asthma and Allergy Awareness Month. This month is dedicated to teaching others about asthma and allergies to create more awareness and understanding. We also want to help people see beyond asthma and allergies. This year, we aim to do just that through our themes, “More Than Asthma” and “More Than Food Allergies.”
This year’s theme for World Allergy Week is The Global Problem of Food Allergy. To help us take action on food allergies, we are seeking 1,000 individuals to fill out a survey that may take 15-30 minutes (the length of the survey depends on your answers).
The Asthma and Allergy Foundation of America (AAFA) has released the 2019 Spring Allergy Capitals™ report to look at why some locations are more affected than others. Our report ranks the top 100 cities in the nation for spring allergies.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Alpha-gal syndrome (AGS), a food allergy commonly known as red meat allergy, may develop from ticks’ saliva itself, whether a tick has fed on another animal before biting a human or not. This news comes from a study presented for the first time at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology.